Medicine and Dentistry
Cohort Analysis
100%
Human Immunodeficiency Virus
96%
Cystic Fibrosis
78%
COVID-19
54%
Kidney Graft
46%
Infection
42%
Population
40%
Symptom
37%
Patient with Cystic Fibrosis
31%
Ivacaftor
30%
Immunosuppressive Treatment
27%
Lumacaftor
26%
Cervical Cancer
24%
Population Dynamics
24%
Uterine Cervix Dysplasia
23%
Bacteremia
23%
Hemodialysis
23%
Fungemia
23%
Cystic Fibrosis Transmembrane Conductance Regulator
21%
Severe Acute Respiratory Syndrome Coronavirus 2
20%
Antiinfective Agent
17%
Screening
17%
Cervical Cancer Screening
17%
Disease
17%
Antibiotics
17%
Antibiotic Therapy
17%
Highly Active Antiretroviral Therapy
17%
Tezacaftor
15%
End Stage Renal Disease
15%
Hazard Ratio
15%
Diagnosis
15%
Human Immunodeficiency Virus Infection
14%
Drug Megadose
13%
Staphylococcus Aureus
13%
Cohort Study
12%
Placebo
12%
Mixed Infection
12%
Cross Sectional Study
11%
Zanamivir
11%
Oseltamivir
11%
Mitochondrial DNA
11%
Macrogol
11%
Sarcoidosis
11%
Achromobacter
11%
Extrapulmonary Tuberculosis
11%
Early Intervention
11%
Epstein Barr Virus
11%
Lower Respiratory Tract
11%
Sulfhemoglobinemia
11%
Adipocyte
11%
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
93%
Cystic Fibrosis
69%
Infection
43%
Hemodialysis
27%
Symptom
23%
Dicarbonate
23%
Cystic Fibrosis Transmembrane Conductance Regulator
21%
Antiinfective Agent
19%
End Stage Renal Disease
17%
Disease
17%
Tezacaftor
15%
Ivacaftor
15%
SARS Coronavirus
15%
Malignant Neoplasm
14%
Comorbidity
13%
Bloodstream Infection
12%
Base
12%
HIV
11%
Human Papillomavirus
11%
Sarcoidosis
11%
Pandemic Influenza
11%
Programmed Death 1 Receptor
11%
Oseltamivir
11%
Influenza A (H1N1)
11%
Antibiotic Agent
11%
Vaccine
11%
Hematologic Disease
11%
Moxifloxacin
11%
Staphylococcal Bacteremia
11%
Vaccination Policy
11%
Adverse Event
11%
Miliary Tuberculosis
11%
Pyelonephritis
11%
Bacteremia
11%
Community Acquired Pneumonia
11%
Fungemia
11%
Bacterial Endocarditis
11%
Severe Acute Respiratory Syndrome
11%
Staphylococcus Epidermidis
11%
Achromobacter
11%
Patient Registry
11%
Pharmacokinetics
11%
Prospective Cohort Study
11%
Virus DNA
11%
Epstein-Barr Virus
11%
Aciduria
11%
Secretin
10%
Influenza A Virus (H1N1)
8%
Infectious Agent
8%
Dyspnea
6%
Immunology and Microbiology
Human Immunodeficiency Virus
78%
Population
23%
Human Immunodeficiency Virus Infection
16%
Mouse
15%
Prevalence
14%
Cancer Screening
14%
Screening
14%
Hepatitis B Virus
13%
Coinfection
12%
Cytomegalovirus
11%
Aspergillus
11%
Biofilm
11%
Regulatory B Cells
11%
Decision Making
11%
Human Immunodeficiency Virus 1
11%
Coenzyme
11%
Listeria monocytogenes
11%
Adipocyte
11%
Hepatitis C
11%
Achromobacter Xylosoxidans
11%
Bursitis
11%
Mycobacterium malmoense
11%
Hepatitis B Vaccine
11%
Staphylococcus Epidermidis
11%
Glatiramer Acetate
11%
Drug Megadose
11%
Sow (Swine)
11%
Aspergillus fumigatus
11%
Immunosuppression
11%
Genotype
11%
Hemocyte
11%
Nontuberculous mycobacteria
11%
Gram-Negative Bacteria
11%
Ocrelizumab
11%
Ureaplasma urealyticum
11%
Hypogammaglobulinemia
11%
Peripheral Blood Mononuclear Cell
9%
T Cell
9%
Vaccination Policy
8%
Mould
7%
Back
5%
Mycobacterium abscessus
5%
Aortic Wall
5%
Lung Transplantation
5%
Sex Difference
5%
Fomite
5%
X-Ray Computed Tomography
5%
Serology
5%